American Society of Clinical Oncology guidelines for defining comorbidity profiles in patients being considered for chemotherapy for advanced pancreatic cancer

	Favorable	Relatively favorable
Hemoglobin (without transfusion support)	≥10 g/dL	≥9 g/dL
Platelet count (without transfusion support)	≥100,000/microL	≥75,000/microL
Bilirubin	≤1.5 times ULN	≤1.5 times ULN
INR	≤1.5 times ULN	≤1.5 times ULN
Albumin	≥3 g/dL	≥3 g/dL
CrCl	≥60 mL/minute/1.73 m²	≥60 mL/minute/1.73 m²
Comorbid condition requiring ongoing active medical care (eg, CHF, COPD, uncontrolled diabetes, neurologic disorders)	Absent	May be present, but not poorly controlled

ULN: upper limit of normal; INR: international normalized ratio; CrCl: creatinine clearance; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease.

Reference: Sohal DPS, Kennedy EB, Khorana A, et al. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018.

Graphic 118194 Version 1.0

خرید پکیج

American Society of Clinical Oncology guidelines for defining comorbidity profiles in patients being considered for chemotherapy for advanced pancreatic cancer